secwatch.observer — SEC 8-K summary
======================================

Issuer:     PFIZER INC (PFE)
CIK:        0000078003
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0000078003-26-000053
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pfizer Q1 revenue $14.5B (+2% op); adj EPS $0.75 (-18%); reaffirms FY26 guidance
--------------------------------------------------------------------------------

- Revenue $14.45B, up 2% operationally; ex-COVID products grew 7% op; launched/acquired products up 22% op.
- Reported diluted EPS $0.47, adjusted $0.75 vs $0.92 in Q1 '25 (-18%).
- Reaffirmed FY26 revenue guidance $59.5-62.5B and adj EPS $2.80-3.00.
- Positive Phase 3 readouts for Elrexfio (RRMM), Padcev (MIBC), Talzenna+Xtandi, Lyme vaccine 73-75% efficacy.
- Exited ViiV Healthcare for $1.875B; Vyndamax patent settlement extends to 2031; GLP-1 collaboration in China for ecnoglutide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/0000078003-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/78003/000007800326000053/pfe-20260505.htm
  HTML page:      https://secwatch.observer/filing/0000078003-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer